Pharmaceutical formulation development is the process of designing and refining a medicine's composition and manufacturing approach so that the product meets its intended quality and performance requirements. The work involves understanding the active pharmaceutical ingredient (API), excipients, dosage form, process conditions and target market.
KMS Pharma supports formulation development for complex and differentiated products by defining the target product profile, identifying critical quality attributes, assessing formulation and process risks, and applying Quality by Design (QbD) and Design of Experiments (DoE) where appropriate. The aim is to build a sound technical basis for further development, stability studies, scale-up and regulatory filing.
What is pharmaceutical formulation development?
Formulation development translates a product concept into a defined dosage form with measurable quality and performance characteristics. Scientists evaluate how the API behaves, which excipients may be suitable, and how manufacturing conditions influence the finished product.
The right approach depends on the product's properties and intended use. Solubility, stability, dose, route of administration, release profile and manufacturability can all influence formulation decisions. A formulation that performs well in a small laboratory batch must also be assessed for reproducibility and its ability to progress through later development stages.
Understand the API's physical, chemical and performance characteristics.
Select and evaluate excipients based on compatibility and product requirements.
Establish suitable formulation and process parameters through documented studies.
Generate data that informs stability assessment, scale-up and subsequent development decisions.
Define the target product profile and critical quality attributes
A clear target product profile (TPP) helps establish what the medicine is intended to achieve. It can describe the dosage form, strength, route of administration, release characteristics, packaging considerations and relevant quality expectations for the intended market.
From this profile, development teams identify critical quality attributes (CQAs)—the physical, chemical, biological or microbiological characteristics that should remain within appropriate limits to help ensure product quality. The exact attributes vary by product and dosage form.
Target Product Profile
Document the intended product characteristics and development goals before selecting a formulation strategy.
Critical Quality Attributes
Determine which product characteristics require particular attention during development and control.
Material Attributes
Consider API properties, excipient characteristics and material variability that may affect performance.
Development Rationale
Record the scientific reasoning behind formulation choices, study design and quality targets.
Assess formulation and process risks early
Potential risks are easier to investigate when they are considered early in the development programme. An assessment may examine API–excipient compatibility, sensitivity to moisture or temperature, particle-size variation, processing conditions, dosage-form performance and possible changes during storage.
Risk assessment helps teams prioritise experiments and focus resources on variables that may have a meaningful impact on product quality. The findings can guide the selection of materials, process parameters, analytical tests and controls for further studies.
Identify potential risks
Review product knowledge, material properties, process steps and available data to identify variables that may affect quality.
Prioritise investigations
Assess the possible impact of each variable and determine which questions require experimental evidence.
Review and refine
Use study results to update the understanding of product and process risks as development progresses.
How QbD and DoE support formulation development
Quality by Design (QbD) is a systematic approach to development that starts with predefined objectives and builds product and process understanding through scientific knowledge and risk assessment. It encourages teams to consider quality throughout development rather than relying only on end-product testing.
Design of Experiments (DoE) is a statistical approach used to investigate multiple factors in a planned series of experiments. When appropriate, DoE can help teams understand how formulation composition and process parameters influence selected responses, including interactions between variables.
Quality by Design
Connect product goals, quality attributes, risk assessment and process understanding within a structured development strategy.
Design of Experiments
Plan studies to evaluate selected variables efficiently and interpret their effects on relevant product responses.
Evidence-led Decisions
Use experimental findings to inform formulation optimisation and identify areas that need further evaluation.
Process Understanding
Build knowledge of material and process variability to support appropriate controls as development advances.
QbD and DoE are applied according to project objectives, product complexity and available evidence. Their use does not replace sound scientific judgement, suitable analytical methods or product-specific evaluation.
Formulation strategies for complex and differentiated products
Different dosage forms present different development considerations. Oral solid products may require evaluation of flow, compressibility, dissolution and content uniformity. Oral liquids may require attention to solubility, homogeneity, preservative effectiveness and physical or chemical stability. Topical formulations may need assessment of texture, consistency, delivery and product performance.
Sterile injectables and ophthalmic products can involve additional requirements relating to sterility, particulates, compatibility and other product-specific quality attributes. The development plan should reflect the dosage form, API characteristics and applicable regulatory expectations.
For differentiated products, development may require a tailored combination of material characterisation, formulation screening, process evaluation and analytical testing. The work should be planned around the specific technical challenges rather than applying the same approach to every product.
Why stability studies and consistency matter
Stability studies help assess how a pharmaceutical product's quality changes over time under defined storage conditions. Depending on the product, testing may evaluate attributes such as assay, degradation products, dissolution, appearance, pH or other relevant parameters.
Stability findings can inform formulation selection, packaging considerations, storage recommendations and the data needed for regulatory submissions. Study design and interpretation should follow the applicable requirements for the product and target market.
Consistency is also important as the process develops. Understanding material variability and process parameters can help teams investigate differences between batches and establish an appropriate basis for reproducible manufacturing.
Prepare the formulation for scale-up and technology transfer
Conditions that work at laboratory scale may behave differently when equipment, batch size, mixing, heat transfer or processing time changes. Scale-up therefore requires a considered review of the formulation and process, supported by relevant data and documented knowledge.
Review development data
Bring together formulation composition, process parameters, analytical results, risk assessments and relevant study records.
Assess scale-dependent variables
Consider how equipment and operating conditions may influence process behaviour and critical quality attributes.
Support knowledge transfer
Document process understanding, testing requirements and control considerations for the receiving technical or manufacturing team.
A structured technology-transfer process helps preserve important product and process knowledge as work moves between development and manufacturing teams. The required activities depend on the product, manufacturing arrangement and stage of development.
Connect formulation development with regulatory filing
Regulatory submissions rely on a clear, consistent explanation of the product, its quality, the manufacturing process and the evidence supporting the proposed specifications. Formulation composition, analytical methods, stability results, process controls and development rationale may all contribute to the technical documentation.
Considering regulatory expectations during development can help teams identify data needs and organise records in a more useful way. Requirements vary by product type, submission pathway and target market, so the development strategy should be aligned with the relevant guidance and requirements.
Regulatory readiness is not guaranteed by any single study or development method. It depends on the overall quality and completeness of the product-specific evidence and documentation.
KMS Pharma's approach to formulation development
KMS Pharma supports the development of robust formulations for complex and differentiated pharmaceutical products. The approach begins by defining the target product profile and critical quality attributes, followed by assessment of formulation and process risks relevant to the project.
QbD and DoE methods can be used where suitable to build product and process understanding and to guide formulation optimisation. Development activities are considered in relation to stability studies, scale-up requirements and the information needed to support regulatory filing.
A well-planned formulation programme connects product goals, risk assessment, experimental evidence and process understanding from the early stages of development.
The specific scope of work depends on the product's characteristics, development stage, technical requirements and intended market. Aligning the programme with these factors helps define relevant studies, milestones and documentation needs.
What to consider when selecting a formulation development company
When evaluating a pharmaceutical formulation development company, look at how its scientific capabilities match the product's needs. A useful discussion should cover the technical challenge, available product data, planned studies, quality requirements and the intended path towards scale-up or filing.
Relevant experience with the intended dosage form and product complexity.
A clear approach to target product profile and critical quality attributes.
Risk assessment and suitable use of QbD or DoE where appropriate.
Access to relevant analytical evaluation and stability-study planning.
Documented development knowledge that can support scale-up and technology transfer.
An understanding of documentation and regulatory requirements for the intended market.
Discussing these points early can help both parties define a realistic development scope, identify information gaps and agree on the evidence needed to evaluate progress.
Discuss your formulation development requirements
Explore how KMS Pharma's formulation development approach can be aligned with your product characteristics, quality objectives, scale-up needs and intended regulatory pathway.
Contact KMS Pharma